Sign inJoin waitlistJoin the waitlist

David Avigan

Director, BIDMC Cancer Center · Beth Israel Deaconess Medical Center

Credentials: · · · ·

History

BIDMC Cancer Center · Beth Israel Deaconess Medical Center
Present
Division of Hematology and Hematologic Malignancies · Beth Israel Deaconess Medical Center
Present
Clinical and Scientific Integration Division · Mass General Brigham
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1992–1995
Internal Medicine
1989–1992
Yale Univ Sch of Med
1985–1989

Research

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a…
The Lancet · 2021 · 1,514 citations
Interleukin-2 and regulatory T cells in graft-versus-host disease
New England Journal of Medicine · 2011 · 929 citations
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Journal of Clinical Oncology · 2016 · 869 citations

Jacalyn Rosenblatt
70 papers
DK
Donald Kufe
48 papers
RJ
Robin Joyce
29 papers
Ken Anderson
20 papers
JL
James Levine
18 papers
Jon Arnason
18 papers
Paul Richardson
18 papers
Robert Soiffer
17 papers
Nikhil Munshi
15 papers
Joseph Antin
14 papers
Richard Stone
14 papers
AP
Athalia Pyzer
13 papers

Grants

Personalized Adoptive T-Cell Therapy for AML
National Cancer Institute · R01
Contact PI · $3.6M · Beth Israel Deaconess Medical Center
2021–2026
Personalized Vaccine for Patients with AML
National Cancer Institute · R01
Contact PI · $3.6M · Beth Israel Deaconess Medical Center
2016–2024
High-Efficiency Microfluidic Cell Fusion for Dendritic Cell/Tumor Cell Vaccine Production
National Cancer Institute · R21
PI · $428.5K · Massachusetts Institute of Technology
2021–2024
Targeting PML for Leukemia Therapy
National Cancer Institute · R01
Contact PI · $457K · Beth Israel Deaconess Medical Center
2010–2021

Clinical trials

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Principal investigator · Recruiting · Phase 1
David Avigan
2026–2030
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 1
David Avigan
2025–2030
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1, Phase 2
Beth Israel Deaconess Medical Center
2014–2025
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Principal investigator · Terminated · Phase 2
Beth Israel Deaconess Medical Center
2011–2016